The largest study to date of a controversial cardiac surgery drug shows it increases death rates and damages kidney function. Aprotinin, a drug used to limit bleeding, was temporarily suspended from marketing in the U.S. in November 2007 after a small Canadian study was stopped because similar findings were discovered.